Abstract：
Immune checkpoint inhibitors (ICIs) are essential for urothelial carcinoma (UC) treatment. Fibroblast growth factor receptor (FGFR) alterations, as common oncogenic drivers in UC, have been reported to drive T cell depletion of UC immune microenvironment via up-regulating FGFR signaling, which indicated FGFR alterations potentially result in reduced response to ICIs. In addition, the selective pan-FGFR inhibitor showed better clinical benefit in clinical trials, indicating FGFR has emerged as critical therapeutic target via inhibiting FGFR signaling. The present study aims to evaluate prognosis and response to ICIs between FGFR-altered UC patients and FGFR-wildtype UC patients via 1963 UC patients and offers new insights into personalized precision therapy and combination therapy for UC.
摘要：
免疫检查点抑制剂（ICIs）对于尿路上皮癌（UC）治疗至关重要。成纤维细胞生长因子受体（FGFR）改变，作为UC中常见的致癌驱动因素，据报道，通过上调FGFR信号驱动UC免疫微环境的T细胞耗尽，这表明FGFR改变可能导致对ICIs的反应降低。此外,选择性pan-FGFR抑制剂在临床试验中显示出更好的临床益处，表明FGFR已通过抑制FGFR信号传导成为关键的治疗靶标。本研究旨在通过1963年UC患者评估FGFR改变的UC患者和FGFR野生型UC患者之间的预后和对ICI的反应，并为UC的个性化精准治疗和联合治疗提供新的见解。
